- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
Cancer vaccines archived long-term survival for advanced refractory tumors
Cancer vaccines archived long-term survival for advanced refractory tumors . Cancer vaccines have come out to achieve long-term survival for patients with advanced refractory tumors,
For refractory tumors, a variety of therapeutic cancer vaccines have come out, and advanced patients can achieve long-term survival
Speaking of the beneficiaries of cancer vaccines, there are actually many advanced cancer patients.
The most exciting news recently is the universal vaccination of COVID-19 vaccine. But who would have thought that the original intention of the COVID-19 pneumonia vaccine (Pfizer vaccine) was to prevent cancer. In other words, the COVID-19 vaccine is an “unexpected product” in the process of developing a cancer vaccine.
As for the beneficiaries of cancer vaccines, there are actually many patients with advanced cancer.
After 6 injections, the cancer cells basically disappeared, and after 10 injections, a strong anti-cancer response was seen
Marc Baum was diagnosed with bladder cancer after checking for bleeding urine in a urine test in March 2018. He used almost all the usual steps to treat his bladder cancer, including two surgical operations in three months , Radiotherapy and chemotherapy.
But doctors hope that further measures can be taken to prevent the recurrence of cancer-injections of therapeutic cancer vaccines.
According to the results just reported at the annual meeting of the American Association for Cancer Research (AACR), a vaccine that precisely targets cancer has proven safe and feasible in early clinical trials.
Baum and 12 other patients received 10 custom-designed vaccinations over the course of six months.
The 57-year-old said: “The treatment is quite smooth. The important thing is that it has no serious side effects and will not cause any harm to the human body.”
Dr. Thomas Marron, the principal investigator of the Icahn School of Medicine at Mount Sinai in New York City, said laboratory tests have shown that vaccine injections can indeed promote the immune system response. Over time, you can see T cells (i.e. the immune system). The number of white blood cells) slowly increases over time, but larger follow-up tests are needed to determine how effective the vaccination is to kill cancer cells in the body.
10 injections are planned this time, and the treatment results are amazing! After 6 injections, basically no cancer cells can be seen. After 10 injections, the immune system can see a truly powerful anti-cancer response.
Marron said that the 13 participants in this early trial had a variety of different cancers, including multiple myeloma, breast cancer, bladder cancer, lung cancer and head and neck cancer.
New cancer vaccine gains momentum, 4 patients survived 880 days without cancer
The protagonist of the aforementioned Baum’s anti-cancer experience is a new personalized cancer vaccine-PGV-001 that has performed well at the AACR annual meeting.
Different from traditional cancer vaccines, the personalized cancer vaccine (PGV-001) is an adjuvant therapy vaccine specially used after standard treatment, which helps to remove residual cancer cells in the body and prolong the survival of patients.
In order to explore the safety of cancer vaccines, in this study, 13 patients were included in the cancer vaccine treatment of the Mount Sinai team, including10 solid tumor patients and 3 multiple myeloma patients.
Surprisingly, in actual treatment, the overall tolerance of patients receiving cancer vaccines is good. After 880 days (2 and a half years) of follow-up, 4 patients were still alive without cancer, and 4 patients were still receiving treatment. Only one-third of patients have mild injection site reactions, and the overall treatment effect is very good!
This cancer vaccine is still in early clinical trials. In addition, dendritic cell vaccines in some countries have officially entered clinical applications. Some early cancer patients can consider using vaccines combined with adjuvant radiotherapy and chemotherapy after surgery to kill residual cancer cells, generate immune memory, and prevent cancer recurrence and metastasis. .
When it comes to therapeutic vaccines, I have to mention that the world’s first and only cancer treatment vaccine approved by the US Food and Drug Administration is Provenge (sipuleucel-T), which was approved for use on April 29, 2010. For the treatment of asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC), this is the first time that dendritic cell vaccines have realized the idea of using the patient’s own immune system to attack cancer cells.
After more than 20 years of unremitting efforts, medical oncology researchers continue to innovate, striving to make cell therapy more convenient, safe, efficient and minimally invasive.
Frozen microneedle technology efficiently delivers dendritic cell vaccines and significantly delays tumor growth
On May 3, Professor Xu Chenjie from City University of Hong Kong reported in an internationally renowned journal that they have developed a new generation of microneedle technology that can deliver dendritic cell (DC) vaccines under the skin through minimally invasive technology.
Research results show that this breakthrough technology can trigger a powerful immune response against tumors in mice, providing a simple, safe, efficient and minimally invasive strategy for cell therapy.
In mouse experiments, cells delivered by frozen microneedles can maintain their viability and proliferation ability.
In addition, frozen microneedles are also suitable for packaging other types of therapeutic cells to maximize the retention of the biological activity of the therapeutic agent.
The elite force of the human immune system: dendritic cells
Dendritic cells are a group of heterogeneous immune cells with the strongest antigen-presenting function. They are the only full-time antigen-presenting cells that can activate naive T cells, so they are also called “sentinels” of the immune system. Dendritic cells are the central link of the human immune response, so they are widely used in cancer treatment, especially cancer vaccine research.
In 2011, the Nobel Prize in Medicine was awarded to Professor Steinman, who has made outstanding contributions to the field of dendritic cell vaccines. He found that dendritic cells extend out with many dendritic protrusions, hence the name.
The human body has dendritic cells, but because the number and vitality are not enough to destroy cancerous cells, researchers have gone through a large number of clinical trials to separate the precursor cells of dendritic cells from the blood in a specific way. With the help of a specific messenger, the cells isolated in the test tube can gain immunity. When the current somatic cells mature into dendritic cells, they can capture specific tumor antigens and effectively kill cancer cells.
A variety of therapeutic cancer vaccines have come out, and patients with advanced stages start a long-term survival mode
In fact, dendritic cell vaccines have already made many major breakthroughs in animal experiments and early clinical trials. Among them, the development of dendritic cell vaccines for brain tumor, kidney cancer, and melanoma has entered the phase III clinical trial stage and is expected to be marketed. Cancer-free Homeland (400-626-9916) specifically listed some blockbuster studies for everyone by consulting a large amount of literature. If you want to know more detailed clinical trials, you can call for consultation.
1) The three-year survival period of the new glioma vaccine has increased by 84%! lead to uproar!
Recently, scientists from the German National Cancer Center have developed a peptide vaccine against IDH1 mutations. This vaccine is very convenient to use and can be injected subcutaneously.
It is worth mentioning that the vaccine successfully activated a targeted immune response in 93.3% of patients. The 2 patients who failed to activate the body’s immune response had tumor recurrence within 2 years of treatment, and the entire group of patients was 3 years old. The survival rate is as high as 84%.
Judging from the above preliminary results, IDH1 vaccine is safe and effective.
2) The dawn of a new type of dendritic cell vaccine has appeared, with an overall survival time of 76% at 15 months!
AV-GBM-1 is a patient’s autologous specific dendritic cell vaccine, Has shown great potential in prolonging the mid-term overall survival of newly diagnosed glioblastoma patients.
The 15-month overall survival rate of the 50 evaluable patients who received AV-GBM-1 treatment was 76%, while the 12-month and 15-month overall survival rates of the 287 patients in the control group who received standard treatment were respectively 61% and 48%. This shows that the 15-month overall survival rate of patients receiving AV-GBM-1 treatment has increased by 28%, and the effect is particularly significant
3) Effective rate doubles, new dendritic cell vaccine ilixadencel enters the first-line treatment of kidney cancer
ilixadencel is an allogeneic dendritic cell (DC) vaccine. Studies have shown that the first-line treatment of newly diagnosed advanced metastatic renal cell carcinoma (mRCC) patients by ilixadencel in combination with the targeted anticancer drug sunitinib (Suttan, common name: sunitinib) is comparable to that of patients treated with sunitinib alone. Compared with, the total remission rate is doubled, the complete remission rate is higher, and the remission is more lasting!
Currently, there are dendritic cell vaccines in Germany and Japan for clinical adjuvant treatment of a variety of cancers, such as
Lung cancer, liver cancer, kidney cancer, breast cancer, skin cancer, ovarian cancer, lymphoma
Wait, this is a new hope for the treatment of cancer patients. Patients who want to seek the help of new treatment technologies at home and abroad can first submit their medical records to the Cancer-Free Homeland Medicine Department (400-626-9916) for preliminary evaluation.
In addition, authoritative studies have found that dendritic cells may play a role in SARS-CoV-2 infection. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19 and is one of the Coronavirus family of the Coronavirus family. Therefore, the use of dendritic cell vaccine therapy may bring additional benefits to the elderly, because most elderly people are adversely affected by COVID-19 and their immune systems are relatively fragile, so they can be used as an immune enhancement method, so that the immune system can be at the same time Works on tumors and viruses.
Cancer vaccines archived long-term survival for advanced refractory tumors
(source:internet, reference only)